SRI developed halofantrine for the U.S. Army from 1965 to 1975 as a treatment for drug-resistant malaria. Distributed by the World Health Organization (WHO), the drug has saved countless lives. The Food and Drug Administration (FDA) approved halofantrine as an antimalarial in 1992 under the SmithKline Beecham (now GlaxoSmithKline) brand name, Halfan®.
SRI researchers study the cells of the long-living rodent to find new drug targets for Alzheimer’s, Parkinson’s, and other neurodegenerative disorders.
SRI scientists are developing a cell-based platform using an often-undervalued subset of helper T cells to deliver potent antitumor proteins for solid tumors, overcoming dose-related toxicities.
Ravenswood delivers high-fidelity training experiences to improve military readiness and performance.